Is Moderna Stock Outperforming Its Rivals?
Moderna‘s stock has heavily underperformed over the past year, exhibiting negative returns and deep unprofitability, a stark contrast to many tech peers. A closer look reveals sharply declining revenue and significant losses, reflecting reduced COVID-19 vaccine demand. Its future hinges on successful pipeline diversification into RSV, flu, and oncology, offering a high-risk, high-reward profile in the evolving biotech landscape, with management aiming for breakeven by 2028 through cost-cutting and new product launches.
- MRNA’s -157.3% operating margin, lowest, stems from declining vaccine sales & R&D costs; AAPL’s 31.9% is driven by high-margin services.
- MRNA’s -56.4% revenue growth lags peers due to waning COVID vaccine demand and slow RSV vaccine uptake, unlike HPE’s AI system boost.
- MRNA’s -22.4% stock drop and -3.9 PE reflect investor concerns over post-pandemic losses, lowered guidance, and cash burn.
Here’s how Moderna stacks up across size, valuation, and profitability versus key peers.
| MRNA | HPQ | HPE | IBM | CSCO | AAPL | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 12.1 | 21.4 | 32.4 | 285.5 | 307.7 | 4,079.8 |
| Revenue ($ Bil) | 2.2 | 55.3 | 34.3 | 65.4 | 57.7 | 408.6 |
| PE Ratio | -3.9 | 8.4 | 569.0 | 36.1 | 29.8 | 41.1 |
| LTM Revenue Growth | -56.4% | 3.2% | 13.8% | 4.5% | 8.9% | 6.0% |
| LTM Operating Margin | -157.3% | 6.6% | 4.8% | 17.7% | 22.5% | 31.9% |
| LTM FCF Margin | -120.9% | 5.1% | 1.8% | 18.1% | 22.1% | 23.5% |
| 12M Market Return | -22.4% | -28.7% | 15.4% | 40.8% | 33.9% | 7.6% |
For more details on Moderna, read Buy or Sell MRNA Stock. Below we compare MRNA’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| MRNA | -56.4% | – | -52.6% | -64.2% | 6.4% |
| HPQ | 3.2% | 3.2% | -0.3% | -14.6% | |
| HPE | 13.8% | 13.8% | 3.4% | 2.2% | |
| IBM | 4.5% | – | 1.4% | 2.2% | 5.5% |
| CSCO | 8.9% | 5.3% | -5.6% | 10.6% | |
| AAPL | 6.0% | – | 2.0% | -2.8% | 7.8% |
Operating Margin Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| MRNA | -157.3% | – | -123.3% | -62.8% | 49.9% |
| HPQ | 6.6% | 6.6% | 7.8% | 7.9% | |
| HPE | 4.8% | 4.8% | 8.3% | 8.4% | |
| IBM | 17.7% | – | 16.1% | 15.9% | 13.5% |
| CSCO | 22.5% | 22.1% | 24.1% | 27.3% | |
| AAPL | 31.9% | – | 31.5% | 29.8% | 30.3% |
PE Ratio Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| MRNA | -3.9 | – | -4.5 | -8.1 | 8.5 |
| HPQ | 8.4 | 12.2 | 10.6 | 8.2 | |
| HPE | 569.0 | 495.9 | 8.6 | 10.2 | |
| IBM | 36.1 | – | 33.6 | 19.9 | 77.5 |
| CSCO | 29.8 | 23.1 | 19.8 | 15.5 | |
| AAPL | 41.1 | – | 41.0 | 31.3 | 21.1 |
Still not sure about MRNA stock? Consider portfolio approach.
Portfolios Win When Stock Picks Fall Short
Individual stocks can soar or tank but one thing matters: staying invested. The right portfolio can help you stay invested, capture upside and mitigate the downside associated with any individual stock.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.